Search research articles
Contact Us
Filters
Showing results (221-230 of 319) with videos related to
Page
of 32
Sort By:
Future Oncology (London, England)
|
August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies
Lawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN Task Force Report: Bone Health in Cancer Care
Julie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2020
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Carlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time
Matthew R Smith, Fred Saad, Stephane Oudard, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 9, 2023
Metabolic reprograming and increased inflammation by cadmium exposure following early-life respiratory syncytial virus infection-the involvement of protein S-palmitoylation
Zachery R Jarrell, Choon-Myung Lee, Ki-Hye Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2004
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
William K Oh, Philip W Kantoff, Vivian Weinberg, et al.
Journal of Occupational and Environmental Medicine
|
December 5, 2019
Exposure to Heptachlorodibenzo-p-dioxin (HpCDD) Regulates microRNA Expression in Human Lung Fibroblasts
Collynn F Woeller, Thomas H Thatcher, Juilee Thakar, et al.
The Lancet. Oncology
|
April 18, 2014
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
Bertrand Tombal, Michael Borre, Per Rathenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L Shapiro, Catherine Van Poznak, Christina Lacchetti, et al.
European Urology Oncology
|
November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial
Joan Carles, Bertrand Tombal, Maha Hussain, et al.
Page
of 32
Search research articles
Search
Showing results (221-230 of 319) with videos related to
Sort By:
Page
of 32
Future Oncology (London, England)
|
August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies
Lawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN Task Force Report: Bone Health in Cancer Care
Julie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2020
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Carlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time
Matthew R Smith, Fred Saad, Stephane Oudard, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 9, 2023
Metabolic reprograming and increased inflammation by cadmium exposure following early-life respiratory syncytial virus infection-the involvement of protein S-palmitoylation
Zachery R Jarrell, Choon-Myung Lee, Ki-Hye Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2004
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
William K Oh, Philip W Kantoff, Vivian Weinberg, et al.
Journal of Occupational and Environmental Medicine
|
December 5, 2019
Exposure to Heptachlorodibenzo-p-dioxin (HpCDD) Regulates microRNA Expression in Human Lung Fibroblasts
Collynn F Woeller, Thomas H Thatcher, Juilee Thakar, et al.
The Lancet. Oncology
|
April 18, 2014
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
Bertrand Tombal, Michael Borre, Per Rathenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L Shapiro, Catherine Van Poznak, Christina Lacchetti, et al.
European Urology Oncology
|
November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial
Joan Carles, Bertrand Tombal, Maha Hussain, et al.
Page
of 32